GlassScriptPhysician profile
Emily Kendrick
NPI 1417472457
$2,948.22
in general payments reported to CMS, 2019-2025
13 companies · $824 in 2025
The $824 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $601 · 2023: $391 · 2024: $681 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,896.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $685.15 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $671.78 | 2021-2025 | Dupixent |
| Genzyme Corporation | $558.57 | 2021-2025 | |
| Optinose US, INC. | $298.64 | 2021-2022 | |
| Kaleo, INC. | $177.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $112.25 | 2021 | |
| Aerin Medical INC. | $107.70 | 2022-2025 | |
| Inspire Medical Systems, INC. | $95.43 | 2023-2025 | Inspire |
| Smith+Nephew, INC. | $87.67 | 2025 | Coblation, Halo |
| Novartis Pharmaceuticals Corporation | $67.52 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $36.39 | 2024 | Voquezna |
| Genentech USA, INC. | $27.34 | 2023 | Xolair |
| Novo Nordisk INC | $21.98 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.